Open Journal Systems

Cuidados de enfermería en pacientes con trombólisis e infarto agudo del miocardio

Ma. de Lourdes Arévalo-Rodríguez, Irma González-Cano, Ana Isabel Moreno-Ortíz, Ma. del Carmen Lira-Góngora

Resumen

Se estudiaron los efectos adversos que acompaña la administración de estreptocinasa intravenosa en pacientes que presentaron infarto del miocardio agudo de menos de 6 horas de evolución desde el inicio del dolor, fueron 63 pacientes del sexo masculino y 4 del sexo femenino, se utilizó 1.5 millones de unidades de estreptocinasa en el lapso de una a través de una bomba de infusión.

Los hallazgos fueron en su mayoría sangrados menores en los sitios de punción o incisión vascular manejados por medio de compresión local. Los sangrados mayores fueron del tubo digestivo y hematuria macroscópica y ninguno de ellos requirió de transfusión sanguínea, las reacciones alergo-anafilácticas se manifestaron principalmente por fiebre, no hubo edema angioneurótico ni choque anafiláctico, no se requirió de esferoides y la fiebre se controló por medios físicos. No hubo mortalidad relacionada con el procedimiento.

Palabras clave

Atención de Enfermería; Atención Dirigida al Paciente; Infarto del Miocardio; Trombosis; Enfermería

Texto completo:

PDF

Referencias

National Center For Health Statistic: Monthly Vital Statistic report, Vol. 33 No. 13, Sept. 26, 1985.

National Center For Health Statistics: Detailed diagnosis and procedures for patients discharged from short-X Stay hospitals, United States,1984, data from the national Health Survey Series, Vol.13No. 86.

De Wood M-,S(JoresJ, Notske Retal: Prevalence of total coronary occlusion during the early hour transmural myocardial infarction. N Engl J Med. 303: 897. 1980.

Sanz O, Castañer A, Betriu A et al. Determinants of prognosis in survivors of myocardial infarction: A prospective clinical angiographic study. N Eng! J Med 1982306: 1065.

Chadler A, Chapman I, Erhardt L, et al. Coronary Thrombosis in myocardial infarction. AM J Cardiol 34: 8323, 1974.

Davies M, Woolf N, Robertson W. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br. Heart J. 38: 659.1976.

Horie T, Sekiguchi M, Hirosawa K. Coronacy thrombosis in pathogenesis of acute myocardial infarction. Histopathological study of coronary arteries in 108 necropsied cases using serial section. Br. Heart J. 40: 153,1978.

Forrester JS, Litvack F, Grundfest W et al. A perspective of coronary disease seen through the aneurism of living man. Circulation 75 (3): 505,Rer. 33. Mar.1987.

Verstraete M. Intravenous administration of thrombolytic is the only realistic therapeutic approach in evolving myocardial infarction, Eur Heart J. 1985: 6; 586.

Schroder R, Biamino G, Von Leither E et al. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 1983; 67: 536-548.

Martín G, Stadius M, Davis K el al. The Western Washington intravenous streptokinase trial: Effects of intravenous streptokinase on vessel patency and ventricular function. Circulation 1986; 74: 11-367.

Olson H, Butman S, Piters K, et al A randomized controlled trial of intravenous streptokinase in evolving acute myocardial infarction. Am Heart J 1986; 111: 1021-1029.

Grossman W. Cardiac catheterization and angiography. Editorial LEA Febiger Philadelphia 310-315. 1980.

Thrombolytic therapy in thrombosis: A national intitules of health consensus development conference (symposium). Ann Intern med. 193: 141.1980.

Stamler J. The primery prevention of coronary heart disease. In Braunwald, E. The myocardial failure and infarction. New York. H. P. Publishing Co. J. lnc 1974. pag. 219.

TIMI Study Group: The thrombolysis in myocardial infarction trial. Phase I Findings. N. Engl J. Med.1985,312, 932.

Verstraete M, Bernard R, Bory M, el al Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction Lance! 1985 i; 842

GISSI: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986i; 397-402.

Collen D, Topol E, Tiefenbrunn A, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective, randomized, placebo controlled trial. Circulation 1984; 70:1012.

Verstraete M, Bleifeld W, Brower R, et al. Double blind randomized trial of intravenous tissue type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985 II: 565-569.

Kennedy J, Ritchie J, Davis K, Fritz J: Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309:1477-1482.

ISAM Study group: A prospective trial of intravenous streptokinase in acute myocardial infarction b: Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465-1471.

Anderson J, Marshall H, Askins J, el al. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infaction. Circulation 1984; 70: 606-608.

O´Neill W, Timmis G, Bourdillon P, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986 314; 812-818.

Sharma G, Cella G, Parisi A, et al. Thrombolysis therapy. N Eng J Med. 1982; 306:1268.